Form D · Biotechnology
Strella Biotechnology, Inc.
Seattle, WA · CIK 0001810011
Offering snapshot reported Aug 14, 2026 · SEC filing
- Reported sold
- $1.76M Offering amount: $3.25M
- Investors reported
- 35 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 29, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2026 | Initial | $1,761,591 | No comparison | 35 | SEC filing |
| Sep 10, 2024 | Initial | $5,602,000 | No comparison | 17 | SEC filing |
| Apr 17, 2020 | Initial | $3,316,213 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-594250
Source: Form D, filed Aug 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jacob Jordan | Director, Executive, Promoter |
| Eric Linn | Director |
| Nolan Paul | Director |
| Katherine Sizov | Director, Executive, Promoter |
| Brett Topche | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1601 2nd Ave, Ste 575
Seattle, WA, 98101
Phone: 703-909-4543
Seattle, WA, 98101
Phone: 703-909-4543